Publication | Closed Access

A Phase 1 randomized study compare the pharmacokinetics, safety and immunogenicity of HLX02 to reference CN- and EU-sourced trastuzumab in healthy subjects

Clinical ImmunologyAutoimmune DiseaseHealthy SubjectsMedicineImmunologyClinical TrialsTherapeutic EfficacyAutoimmunityPharmacotherapyImmunotherapyPharmacologyPhase 1Eu-sourced Trastuzumab